Comparative Pharmacology
Head-to-head clinical analysis: RINVOQ versus UPADACITINIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RINVOQ versus UPADACITINIB.
RINVOQ vs UPADACITINIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Janus kinase (JAK) inhibitor; selectively inhibits JAK1 and JAK2, modulating the JAK-STAT signaling pathway involved in cytokine-mediated inflammation and immune responses.
Upadacitinib is a selective and reversible Janus kinase (JAK) inhibitor. It preferentially inhibits JAK1 over JAK2, JAK3, and TYK2. By inhibiting JAK1, it modulates the signaling of multiple cytokines (e.g., IL-6, IL-2, IL-15, and interferons) involved in inflammatory pathways.
15 mg orally once daily, with or without food.
15 mg orally once daily for rheumatoid arthritis; 15 mg once daily for psoriatic arthritis; 15 mg once daily for ankylosing spondylitis; 15 mg once daily for atopic dermatitis; 45 mg once daily for 8 weeks then 15 mg once daily for ulcerative colitis; 45 mg once daily for 8 weeks then 15 mg once daily for Crohn disease.
None Documented
None Documented
Terminal elimination half-life: 6.5–8.9 hours (mean ~7 hours) in healthy subjects; in patients with rheumatoid arthritis, similar half-life supports twice-daily dosing
Terminal elimination half-life is approximately 9 hours (range 5–13 hours), supporting once-daily dosing.
UpToDate: 24% renal (as unchanged drug), 52% fecal (as metabolites); Clinical Pharmacology: 24% renal (unchanged), 52% fecal (metabolites), <1% biliary
Renal (approximately 24% unchanged in urine), fecal (approximately 34% unchanged in feces); total recovery of radiolabeled dose: 88% (36% urine, 52% feces).
Category C
Category C
Janus Kinase (JAK) Inhibitor
Janus Kinase (JAK) Inhibitor